STING1 and neoplasm: In summary, the data reviewed in this article suggest that STING agonists, both alone and as combination therapy with immune checkpoint inhibitors, hold great promise for reprogramming the tumor microenvironment by shifting the suppressive immune compartment towards a pro-inflammatory state.